Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Qilu Pharmaceutical Co., Ltd. clinical trials
The registry lists 210 studies whose lead sponsor is Qilu Pharmaceutical Co., Ltd. or one of 3 companies grouped under it. 127 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Keep track of what changes. Save the Qilu Pharmaceutical Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Qilu Pharmaceutical Co., Ltd..
- Qilu Pharmaceutical Co., Ltd.195 studiesSame company
Something wrong?
- Qilu Pharmaceutical (Hainan) Co., Ltd.8 studies →Subsidiary
Something wrong?
- Shanghai Qilu Pharmaceutical Research and Development Center LTD5 studies →Subsidiary
Something wrong?
- Qilu Puget Sound Biotherapeutics (dba Sound Biologics)2 studies →Subsidiary
Something wrong?
Focus areas
Conditions Qilu Pharmaceutical Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 210. Browse all 210 →
- To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver FibrosisNot yet recruitingNCT07620366Phase 2
- QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJRecruitingNCT07716449Phase 3
- A Study of QLS2401 Injection in Participants With Advanced Prostate CancerNot yet recruitingNCT07869888Phase 1
Sponsor listed in the registry: Shanghai Qilu Pharmaceutical Research and Development Center LTD
- Comparative Study of QL1209 and Perjeta® in Healthy Male ParticipantsNot yet recruitingNCT07861139Phase 1
- A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of QLS2312 InjectionNot yet recruitingNCT07861581Phase 1
Sponsor listed in the registry: Shanghai Qilu Pharmaceutical Research and Development Center LTD
- The First in Human Study of QLS2319 in Healthy Subjects and Cancer CachexiaRecruitingNCT07735104Phase 1/2
- Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal CancerNot yet recruitingNCT07829588Phase 1
- Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug InteractionRecruitingNCT07620041Phase 1
- QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous AdministrationNot yet recruitingNCT07817004Phase 1
Sponsor listed in the registry: Qilu Pharmaceutical (Hainan) Co., Ltd.
- QL0911 for the Treatment of Cancer Treatment-Induced ThrombocytopeniaRecruitingNCT06456528Phase 2/3
- A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung CancerNot yet recruitingNCT07802821Phase 3
- Phase I Study of QLS1510 Tablets in Healthy ParticipantsNot yet recruitingNCT07760077Phase 1
Sponsor listed in the registry: Shanghai Qilu Pharmaceutical Research and Development Center LTD
- A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune DiseasesNot yet recruitingNCT07751315Phase 1
- Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)Not yet recruitingNCT07730632Phase 2
- Phase II Study of QLC2519 in Pediatric Solid Tumor ParticipantsRecruitingNCT07724756Phase 2
- QLF4113 in Participants With Metastatic Prostate CancerNot yet recruitingNCT07636707Phase 1
- Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple MyelomaRecruitingNCT07018050Phase 2
- QLC5508 in Participants With Metastatic Prostate CancerNot yet recruitingNCT07632690Phase 3
- A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate CancerRecruitingNCT07198633Phase 1/2
- Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer PatientsRecruitingNCT07235176Phase 1/2
- A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07138209Phase 3
- QLS1410 in Participants With Uncontrolled HypertensionEnrolling by invitationNCT07489612Phase 2
- QLS5212 for Participants With Advanced Solid TumorsRecruitingNCT07467629Phase 1
- A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor FluctuationsNot yet recruitingNCT07585565Phase 2
- QLS4131 Combination Therapy in Malignant Plasma Cell NeoplasmsNot yet recruitingNCT07560449Phase 2
- Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 DiabetesNot yet recruitingNCT07487103Phase 3
- This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.Not yet recruitingNCT07552376Phase 1
Sponsor listed in the registry: Shanghai Qilu Pharmaceutical Research and Development Center LTD
- QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell CarcinomaRecruitingNCT07463573Phase 3
- Study of QLS1410 in the Treatment of Primary Aldosteronism.Not yet recruitingNCT07550465Phase 2
- A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor PatientsRecruitingNCT06911827Phase 1/2
- A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular DegenerationNot yet recruitingNCT07489586Phase 3
- A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's DiseaseNot yet recruitingNCT07489599Phase 1
- Study of QLS5308 in Patients With Advanced Solid TumorsNot yet recruitingNCT07462442Phase 1
- QLS5132 Combination Therapy in Advanced Solid TumorsNot yet recruitingNCT07453394Phase 1/2
- Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric PatientsNot yet recruitingNCT07455006Phase 3
- QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)Not yet recruitingNCT07450378Phase 3
- QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)Not yet recruitingNCT07441317Phase 3
- QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed DyslipidemiaNot yet recruitingNCT07444086Phase 3
- QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis SuppurativaNot yet recruitingNCT07417917Phase 2
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABPRecruitingNCT07327619Phase 3
- A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male SubjectsNot yet recruitingNCT07400744Phase 1
- Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsRecruitingNCT06671548Phase 3
- QLS12010 in Participants With Moderate-to-severe Rheumatoid ArthritisNot yet recruitingNCT07377773Phase 2
- First in Human Study of QLS5316 in Solid TumorsNot yet recruitingNCT07358884Phase 1
- A Food Effect Study of QLS1410 in Healthy Chinese AdultsNot yet recruitingNCT07358858Phase 1
- A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic DermatitisNot yet recruitingNCT07344051Phase 2
- A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic AnemiaNot yet recruitingNCT07345000Phase 3
- Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant TumorsRecruitingNCT06823609Phase 1
- A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy SubjectsNot yet recruitingNCT07327697Phase 1
- A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic MalignanciesRecruitingNCT07173595Phase 1